• The technology described is VIDAvision. It is used for lung volume analysis in people with advanced emphysema who are being considered for lung reduction procedures.

  • The innovative aspects are that it uses fissure integrity values to assess people with severe emphysema for endobronchial lung volume reduction surgery.

  • The intended place in therapy would be in addition to current lung function and standard CT scans or as an alternative to bronchoscopy in people with severe emphysema.

  • The main points from the evidence summarised in this briefing are from 3¬†studies done in Germany, Brazil and an international multicentre study including 323 adults in hospital settings. VIDAvision may have a role in selecting patients for lung volume reduction surgery but prospective comparative studies are needed.

  • Key uncertainties around the evidence or technology are that it is based on 3 small populations and the evidence was generated using an unvalidated prediction model for patient selection.

  • The cost of VIDAvision is ¬£286 to ¬£446 per scan (excluding VAT). The resource impact may be less than standard care only if its use improves patient selection for lung volume reduction surgery and other invasive treatments.